865 related articles for article (PubMed ID: 21389095)
1. Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication.
Ferain T; Hoveyda H; Ooms F; Schols D; Bernard J; Fraser G
J Pharmacol Exp Ther; 2011 Jun; 337(3):655-62. PubMed ID: 21389095
[TBL] [Abstract][Full Text] [Related]
2. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.
Hunt JS; Romanelli F
Pharmacotherapy; 2009 Mar; 29(3):295-304. PubMed ID: 19249948
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
6. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
7. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
Bleul CC; Farzan M; Choe H; Parolin C; Clark-Lewis I; Sodroski J; Springer TA
Nature; 1996 Aug; 382(6594):829-33. PubMed ID: 8752280
[TBL] [Abstract][Full Text] [Related]
8. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
[TBL] [Abstract][Full Text] [Related]
9. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.
Takashima K; Miyake H; Kanzaki N; Tagawa Y; Wang X; Sugihara Y; Iizawa Y; Baba M
Antimicrob Agents Chemother; 2005 Aug; 49(8):3474-82. PubMed ID: 16048963
[TBL] [Abstract][Full Text] [Related]
10. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro.
Svicher V; Balestra E; Cento V; Sarmati L; Dori L; Vandenbroucke I; D'Arrigo R; Buonomini AR; Van Marck H; Surdo M; Saccomandi P; Mostmans W; Aerssens J; Aquaro S; Stuyver LJ; Andreoni M; Ceccherini-Silberstein F; Perno CF
Antiviral Res; 2011 Apr; 90(1):42-53. PubMed ID: 21349294
[TBL] [Abstract][Full Text] [Related]
12. Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.
Lobritz MA; Ratcliff AN; Marozsan AJ; Dudley DM; Tilton JC; Arts EJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2640-50. PubMed ID: 23529732
[TBL] [Abstract][Full Text] [Related]
13. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
Oberlin E; Amara A; Bachelerie F; Bessia C; Virelizier JL; Arenzana-Seisdedos F; Schwartz O; Heard JM; Clark-Lewis I; Legler DF; Loetscher M; Baggiolini M; Moser B
Nature; 1996 Aug; 382(6594):833-5. PubMed ID: 8752281
[TBL] [Abstract][Full Text] [Related]
14. Isolated human astrocytes are not susceptible to infection by M- and T-tropic HIV-1 strains despite functional expression of the chemokine receptors CCR5 and CXCR4.
Boutet A; Salim H; Taoufik Y; Lledo PM; Vincent JD; Delfraissy JF; Tardieu M
Glia; 2001 May; 34(3):165-77. PubMed ID: 11329179
[TBL] [Abstract][Full Text] [Related]
15. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.
Symons J; van Lelyveld SF; Hoepelman AI; van Ham PM; de Jong D; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2011 Apr; 66(4):890-5. PubMed ID: 21393136
[TBL] [Abstract][Full Text] [Related]
17. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.
Münch J; Ständker L; Pöhlmann S; Baribaud F; Papkalla A; Rosorius O; Stauber R; Sass G; Heveker N; Adermann K; Escher S; Klüver E; Doms RW; Forssmann WG; Kirchhoff F
Antimicrob Agents Chemother; 2002 Apr; 46(4):982-90. PubMed ID: 11897579
[TBL] [Abstract][Full Text] [Related]
18. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
[TBL] [Abstract][Full Text] [Related]
20. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Kang Y; Wu Z; Lau TC; Lu X; Liu L; Cheung AK; Tan Z; Ng J; Liang J; Wang H; Li S; Zheng B; Li B; Chen L; Chen Z
J Biol Chem; 2012 May; 287(20):16499-509. PubMed ID: 22447925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]